Venlafaxine updated on 10-20-2025

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.15 [0.93, 1.42]31%9 studies129,9644,889not evaluable ROB-
Major congenital malformations1.17 [0.97, 1.41]18%9 studies129,9334,889not evaluable ROB-
Congenital heart defects1.29 [0.85, 1.96]51%5 studies35,4073,798not evaluable ROB-
Cardiac septal defects1.21 [0.68, 2.14]69%3 studies17,5283,501not evaluable ROB-
Cleft palate3.39 [1.59, 7.22]-1 studynot evaluable ROB6.24 [2.56; .]
Craniosynostosis1.33 [0.66, 2.67]0%2 studies738not evaluable ROB-
Hypoplastic left heart (HLH/HLHS)7.95 [1.67, 37.85]78%2 studiesnot evaluable ROB15.39 [2.73; .]
Hypospadias1.29 [0.71, 2.31]0%2 studies4,5332,763not evaluable ROB-
Oro-facial clefts2.44 [1.33, 4.48]-1 studynot evaluable ROB4.31 [1.99; .]
Atrial septal defect2.26 [1.03, 4.96]-1 studynot evaluable ROB3.95 [1.21; .]
Coarctation of aorta3.54 [1.56, 8.05]-1 studynot evaluable ROB6.54 [2.49; .]
Gastroschisis4.71 [1.89, 11.75]-1 studynot evaluable ROB8.89 [3.18; .]
Neural Tube Defects2.62 [1.19, 5.76]-1 studynot evaluable ROB4.68 [1.67; .]
Pulmonary valve stenosis2.46 [1.04, 5.81]-1 studynot evaluable ROB4.36 [1.25; .]
Respiratory system anomalies2.17 [1.07, 4.39]-1 study738not evaluable ROB3.76 [1.35; .]
11 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)1.64 [1.33, 2.02]30%6 studies121,2107,381not evaluable ROB2.66 [1.98; .]
Small for gestational age (weight)0.91 [0.83, 1.00]0%2 studies229,7075,628not evaluable ROB-
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Postpartum hemorrhage1.88 [1.39, 2.54]70%2 studies23,8412,153not evaluable ROB3.16 [2.12; .]
Preeclampsia1.57 [1.29, 1.91]-1 study3,3151,113not evaluable ROB2.52 [1.90; .]
Gestational diabetes1.27 [1.09, 1.48]-1 study20,9051,885not evaluable ROB1.86 [1.39; .]

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Low Apgar score (< 7) (at 5 min)1.99 [1.10, 3.61]67%3 studies31,2755,910not evaluable ROB3.40 [1.43; .]
Neonatal medical care1.61 [0.59, 4.41]46%2 studies124141not evaluable ROB-
Persistent pulmonary hypertension0.89 [0.13, 6.37]0%2 studies551not evaluable ROB-
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation3.95 [1.74, 8.97]-1 study57not evaluable ROB7.36 [2.87; .]
Neonatal tachypnea2.36 [1.34, 4.13]-1 study59132not evaluable ROB4.14 [2.02; .]
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions1.73 [1.42, 2.11]0%7 studies5,4941,123not evaluable ROB2.86 [2.20; .]
Elective/induced termination of pregnancy1.97 [1.19, 3.26]67%4 studies2221,026not evaluable ROB3.36 [1.67; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths1.51 [0.53, 4.28]0%2 studies23946not evaluable ROB-
Therapeutic terminations of pregnancy2.39 [1.25, 4.55]0%2 studies9150not evaluable ROB4.21 [1.82; .]

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
ASD (Autism spectrum disorder): Diagnosis1.60 [1.00, 2.57]0%2 studies3641,031not evaluable ROB2.59 [1.03; .]
ASD (Autism spectrum disorder): Diagnosis/Risk1.60 [1.00, 2.57]0%2 studies3641,031not evaluable ROB2.59 [1.03; .]
6 non statistically significant endpoints reported in only one study

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons